Outpatient supportive care following chemotherapy for XXXX .

@entity1 @entity295 @entity4349 @entity2592 @entity3052 @entity1398
Treatment of @entity3052 ( @entity3052 ) involves aggressive myelosuppressive chemotherapy that is generally administered on an inpatient basis. In our centre, @entity3052 therapy has been initiated in hospital and followed by early outpatient supportive care according to guidelines established in 1996. We conducted a review of all @entity1 presenting with @entity3052 in our centre between January 1996 and July 1998 to evaluate the safety and feasibility of early outpatient supportive care. Nineteen consecutive @entity1 treated with induction chemotherapy were analyzed. @entity1 were treated with @entity2592 and an @entity4349 as aggressive @entity3052 induction therapy with the intent for early discharge. Ten @entity1 (53%) were discharged within 10 days of starting induction chemotherapy (median 4.5 days). Reasons for remaining in hospital included @entity295 , serious medical complications, and social and geographic factors. @entity1 discharged early had a median of 1.5 readmissions (range 0-3), but had 30% fewer in-hospital days than inpatients (p = 0.03), and 57% fewer days of in-hospital antibiotic therapy (p = 0.01). There were no significant differences in transfusion requirements or episodes of @entity1398 between the two groups. Thirty-one cycles of consolidation therapy were administered to the 18 @entity1 who survived induction. Early discharge from hospital was achieved for 30 cycles (97%). Nine cycles of consolidation chemotherapy were delivered using outpatient intravenous infusion pumps (29%). This study supports the feasibility and safety of early discharge and outpatient supportive care following chemotherapy for @entity3052 .
